223 related articles for article (PubMed ID: 28445619)
21. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
Diekmann F; Andrés A; Oppenheimer F
Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibitor versus mycophenolic acid as the primary immunosuppression regime combined with calcineurin inhibitor for kidney transplant recipients: a meta-analysis.
Xie X; Jiang Y; Lai X; Xiang S; Shou Z; Chen J
BMC Nephrol; 2015 Jul; 16():91. PubMed ID: 26126806
[TBL] [Abstract][Full Text] [Related]
23. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
24. mTOR Inhibition and Clinical Transplantation: Liver.
Nashan B
Transplantation; 2018 Feb; 102(2S Suppl 1):S19-S26. PubMed ID: 28230639
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitors in pediatric kidney transplantation.
Pape L; Ahlenstiel T
Pediatr Nephrol; 2014 Jul; 29(7):1119-29. PubMed ID: 23740036
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
27. Predictive factors of allosensitization in renal transplant patients switched from calcineurin to mTOR inhibitors.
Ruiz San Millán JC; López-Hoyos M; Segundo DS; Quintela E; Rodrigo E; Gómez-Alamillo C; Romón I; Arias M
Transpl Int; 2014 Aug; 27(8):847-56. PubMed ID: 24707885
[TBL] [Abstract][Full Text] [Related]
28. Peri-operative third party red blood cell transfusion in renal transplantation and the risk of antibody-mediated rejection and graft loss.
Fidler S; Swaminathan R; Lim W; Ferrari P; Witt C; Christiansen FT; D'Orsogna LJ; Irish AB
Transpl Immunol; 2013 Dec; 29(1-4):22-7. PubMed ID: 24090807
[TBL] [Abstract][Full Text] [Related]
29. De novo donor-specific human leukocyte antigen antibodies early after kidney transplantation.
Heilman RL; Nijim A; Desmarteau YM; Khamash H; Pando MJ; Smith ML; Chakkera HA; Huskey J; Valdez R; Reddy KS
Transplantation; 2014 Dec; 98(12):1310-5. PubMed ID: 24879384
[TBL] [Abstract][Full Text] [Related]
30. Systematic Review on Role of Mammalian Target of Rapamycin Inhibitors as an Alternative to Calcineurin Inhibitors in Renal Transplant: Challenges and Window to Excel.
Kumar J; Bridson JM; Sharma A; Halawa A
Exp Clin Transplant; 2017 Jun; 15(3):241-252. PubMed ID: 27915965
[TBL] [Abstract][Full Text] [Related]
31. Characteristics of Circulating Donor Human Leukocyte Antigen-specific Immunoglobulin G Antibodies Predictive of Acute Antibody-mediated Rejection and Kidney Allograft Failure.
Kannabhiran D; Lee J; Schwartz JE; Friedlander R; Aull M; Muthukumar T; Campbell S; Epstein D; Seshan SV; Kapur S; Sharma VK; Suthanthiran M; Dadhania D
Transplantation; 2015 Jun; 99(6):1156-64. PubMed ID: 25629531
[TBL] [Abstract][Full Text] [Related]
32. Clinical and histopathologic features of antibody-mediated rejection among pediatric renal transplant recipients with preformed vs de novo donor-specific antibodies.
Steggerda JA; Kim IK; Haas M; Zhang X; Kang A; Pizzo H; Kamil E; Jordan S; Puliyanda D
Pediatr Transplant; 2017 Dec; 21(8):. PubMed ID: 29159992
[TBL] [Abstract][Full Text] [Related]
33. Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions.
Tanrısev M; Ayna Kılıçaslan T; Çolak H; Ersan S; Yılmaz B; Alp A; Tuğmen C; Sevgili BE
Ann Transplant; 2021 Sep; 26():e932434. PubMed ID: 34531361
[TBL] [Abstract][Full Text] [Related]
34. mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field?
Rostaing L; Kamar N
J Nephrol; 2010; 23(2):133-42. PubMed ID: 20155724
[TBL] [Abstract][Full Text] [Related]
35. Results of early treatment for de novo donor-specific antibodies in pediatric kidney transplant recipients in a cross-sectional and longitudinal cohort.
Charnaya O; Tuchman S; Moudgil A
Pediatr Transplant; 2018 Mar; 22(2):. PubMed ID: 29356221
[TBL] [Abstract][Full Text] [Related]
36. Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation.
Malheiro J; Tafulo S; Dias L; Martins LS; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Transpl Immunol; 2015 Mar; 32(2):66-71. PubMed ID: 25661873
[TBL] [Abstract][Full Text] [Related]
37. De novo DQ donor-specific antibodies are associated with worse outcomes compared to non-DQ de novo donor-specific antibodies following heart transplantation.
Cole RT; Gandhi J; Bray RA; Gebel HM; Morris A; McCue A; Yin M; Laskar SR; Book W; Jokhadar M; Smith A; Nguyen D; Vega JD; Gupta D
Clin Transplant; 2017 Apr; 31(4):. PubMed ID: 28181305
[TBL] [Abstract][Full Text] [Related]
38. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
39. Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors.
Del Bello A; Congy-Jolivet N; Rostaing L; Kamar N
J Hepatol; 2014 Oct; 61(4):963-5. PubMed ID: 24999017
[No Abstract] [Full Text] [Related]
40. CXCR5 + CD8 + T Cell-mediated Suppression of Humoral Alloimmunity and AMR in Mice Is Optimized With mTOR and Impaired With Calcineurin Inhibition.
Han JL; Zimmerer JM; Zeng Q; Chaudhari SR; Hart M; Satoskar AA; Abdel-Rasoul M; Breuer CK; Bumgardner GL
Transplantation; 2024 Mar; 108(3):679-692. PubMed ID: 37872660
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
